Government-run Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the program billions of dollars by next year — well beyond what Wall Street or even the drug’s manufacturer have projected — according to a document obtained by STAT.
Government-run Medicare’s actuaries expect the drug Leqembi, made by the Japanese drugmaker Eisai and sold in partnership with Biogen, to cost the traditional Government-run Medicare program around $550 million in 2024, and the entire Government-run Medicare program $3.5 billion in 2025, a spokesperson for the Centers for Government-run Medicare and Medicaid Services confirmed to STAT. That projection forecasts a large increase in uptake over the next year and a half.
The estimate was buried in a new CMS document that addressed questions about next year’s payments for Government-run Medicare Advantage plans, which cover more than 33 million people and serve as the alternative to the traditional Government-run Medicare program.
Click this link for the original source of this article.
Author: Bob Herman and Rachel Cohrs Zhang
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.